newsfilter
← Latest News
GlobeNewswire·

Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates

- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 - - Start-up activities